Pediatrix Medical Group, Inc. (MD)
NYSE: MD · Real-Time Price · USD
14.19
-0.23 (-1.60%)
At close: May 14, 2025, 4:00 PM
14.19
0.00 (0.00%)
After-hours: May 14, 2025, 4:36 PM EDT
Pediatrix Medical Group Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Pediatrix Medical Group stock ranges from a low of $15 to a high of $20. The average analyst price target of $16.67 forecasts a 17.48% increase in the stock price over the next year.
Price Target: $16.67 (+17.48%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Pediatrix Medical Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $19 → $16 | Hold | Maintains | $19 → $16 | +12.76% | May 12, 2025 |
| Macquarie | Macquarie | Buy Maintains $19 → $20 | Buy | Maintains | $19 → $20 | +40.94% | May 8, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $18 → $16 | Hold | Maintains | $18 → $16 | +12.76% | Apr 11, 2025 |
| UBS | UBS | Hold Maintains $17 → $19 | Hold | Maintains | $17 → $19 | +30.37% | Feb 21, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $15 → $18 | Hold | Maintains | $15 → $18 | +26.85% | Feb 21, 2025 |
Financial Forecast
Revenue This Year
1.93B
from 2.01B
Decreased by -4.37%
Revenue Next Year
1.98B
from 1.93B
Increased by 2.65%
EPS This Year
1.59
from -1.19
EPS Next Year
1.67
from 1.59
Increased by 5.39%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.1B | 2.1B | 2.2B | ||
| Avg | 1.9B | 2.0B | 2.1B | ||
| Low | 1.8B | 1.8B | 1.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.2% | 10.4% | 13.6% | ||
| Avg | -4.4% | 2.6% | 5.0% | ||
| Low | -12.3% | -5.7% | -5.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.70 | 1.89 | 2.10 | ||
| Avg | 1.59 | 1.67 | 1.69 | ||
| Low | 1.38 | 1.40 | 1.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 18.7% | 25.4% | ||
| Avg | - | 5.4% | 1.2% | ||
| Low | - | -11.8% | -18.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.